Detailed Information

Cited 17 time in webofscience Cited 19 time in scopus
Metadata Downloads

Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome

Authors
Shin, Teak JunSong, CherynJeong, Chang WookKwak, CheolSeo, SeongilKang, MinyongChung, JinsooHong, Sung-HooHwang, Eu ChangPark, Jae YoungLee, Hakmin
Issue Date
Jan-2021
Publisher
John Wiley & Sons Inc.
Keywords
metastasectomy; metastatic renal cell carcinoma; outcome; pancreas metastasis; survival prediction
Citation
Journal of Surgical Oncology, v.123, no.1, pp 204 - 213
Pages
10
Indexed
SCIE
SCOPUS
Journal Title
Journal of Surgical Oncology
Volume
123
Number
1
Start Page
204
End Page
213
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/33981
DOI
10.1002/jso.26251
ISSN
0022-4790
1096-9098
Abstract
Background and Objectives Metastatic renal cell carcinoma to the pancreas (PM-RCC) is infrequent; we sought to describe the characteristics of PM-RCC and analyze the outcome following treatment. Methods Data of 3107 mRCC patients treated between 1992 and 2007 from the Korean Renal Cancer Study Group database were obtained to identify 300 (9.7%) PM-RCC patients. Characteristics and survival were analyzed and compared to the rest of the mRCC, according to the timing of metastasis and surgical treatments received. Results PM-RCC was younger at initial diagnosis (55.0 vs. 58.2 years), more frequently in women (30.3% vs. 22.3%), and metachronous (65.3% vs. 41.9%) with a longer disease-free period (82.0 vs. 33.0 months). Overall survival (OS) was significantly better in PM-RCC but pancreas metastasectomy was associated with improved OS only among metachronous PM-RCC. In the 132 metachronous PM-RCC with pancreas metastasectomy, median recurrence-free survival was 17.2 months and we found Heng risk group (hazard ratio [HR] = 2.384, 95% confidence interval [CI] = 1.213–4.684), younger age (HR = 0.965, 95% CI = 0.945–0.987), shorter interval to pancreas metastasis (HR = 0.993, 95% CI = 0.986–0.999), and Eastern Cooperative Oncology Group performance status to be predictive of early progression following pancreas metastasectomy. Conclusion Compared to the other mRCC, PM-RCC demonstrated a favorable prognosis. Pancreas metastasectomy was associated with prolonged survival in the metachronous PM-RCC with a long progression-free period.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Urology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Jae Young photo

Park, Jae Young
Ansan Hospital (Department of Urology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE